Analysts expect Nautilus Biotechnology, Inc. to report revenue of 203,106.13 for Q3 26, against a range of 194,239.13 to 211,973.13. The most recent reported quarter, Q2 26, came in at 190,000.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 190,000.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 211,973.13 | 210,770.45 | 339,951.92 | 778,175.82 | 997,728.81 | 985,402.86 | 4.66 M | 5.24 M | ||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 194,239.13 | 197,585.05 | 319,136.58 | 700,300.06 | 889,398.27 | 918,310.30 | 4.39 M | 4.51 M | ||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 203,106.13 | 204,177.75 | 329,544.25 | 739,237.94 | 943,563.54 | 951,856.58 | 4.52 M | 4.88 M |
Analysts expect Nautilus Biotechnology, Inc. to report earnings per share of -0.15 for Q3 26, against a range of -0.16 to -0.14. The most recent reported quarter, Q2 26, came in at -0.11, a 15.4% beat against the -0.13 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.13 | -0.14 | -0.13 | -0.12 | -0.11 | -0.11 | -0.12 | -0.11 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.14 | -0.15 | -0.13 | -0.15 | -0.15 | -0.14 | -0.12 | -0.12 | -0.14 | -0.13 | -0.10 | -0.12 | -0.14 | -0.11 | -0.09 | -0.09 | ||||||||||
| Low Estimate | -0.18 | -0.17 | -0.15 | -0.17 | -0.17 | -0.16 | -0.14 | -0.14 | -0.16 | -0.15 | -0.12 | -0.14 | -0.16 | -0.13 | -0.11 | -0.11 | ||||||||||
| Consensus Estimate | -0.16 | -0.16 | -0.14 | -0.16 | -0.16 | -0.15 | -0.13 | -0.13 | -0.15 | -0.14 | -0.11 | -0.13 | -0.15 | -0.12 | -0.10 | -0.10 |
Pull Wall Street consensus for Nautilus Biotechnology, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=NAUT&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "NAUT", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=NAUT&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();